KRAS/STK11 co-mutation might drive intrinsic resistance to PD-1/PD-L1 inhibitors, as it was the only marker associated with PD-L1 negativity among 924 intermediate/high TMB lung adenocarcinoma patients (144). The gene discussed is KRAS; the disease is lung adenocarcinoma.